A Post Hoc Analysis of Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod in Phase 3 Trials

被引：0
|
作者：
Harris, S. [1 ]
Southworth, H. [2 ]
Sheffield, J. K. [1 ]
Maddux, R. [1 ]
Cohen, J. [3 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Data Clar Consulting Ltd, Stockport, Lancs, England
[3] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH 44106 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P159
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] GFAP as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 Ozanimod SUNBEAM Trial
    Harris, S.
    Comi, G.
    Cree, B.
    Arnold, D.
    Steinman, L.
    Sheffield, J.
    Southworth, H.
    Kappos, L.
    Cohen, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 121 - 121
  • [2] Hepatic Safety of Ozanimod in Phase 3 Relapsing Multiple Sclerosis Trials
    Comi, Giancarlo
    Selmaj, Krzystof
    Bar-Or, Amit
    Hartung, Hans-Peter
    Havrdova, Eva Kubala
    Sheffield, James
    Minton, Neil
    Afsari, Sonia
    Liu, Hongjuan
    Silva, Diego
    Cohen, Jeffrey
    NEUROLOGY, 2021, 96 (15)
  • [3] Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
    Harris, Sarah
    Comi, Giancarlo
    Cree, Bruce A. C.
    Arnold, Douglas L.
    Steinman, Lawrence
    Sheffield, James K.
    Southworth, Harry
    Kappos, Ludwig
    Cohen, Jeffrey A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (11) : 3722 - 3730
  • [4] Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials
    Rubin, David T.
    Caldera, Freddy
    Cohen, Jeffrey
    Zeuzem, Stefan
    Cheng, Chun-Yen
    Ather, Shabana
    Charles, Lorna
    Sheffield, James K.
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S581 - S581
  • [5] Serum immunoglobulin levels and infection risk in the phase 3 trials of ofatumumab in relapsing multiple sclerosis
    Wiendl, H.
    De Seze, J.
    Bar-Or, A.
    Correale, J.
    Cross, A. H.
    Kappos, L.
    Selmaj, K.
    Das Gupta, A.
    Haering, D. A.
    Jehl, V.
    Kerloeguen, C.
    Pingili, R.
    Su, W.
    Sullivan, R.
    Zalesak, M.
    Hauser, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 233 - 234
  • [6] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [7] Post hoc analysis of cognitive processing speed at time of first confirmed relapse in patients with relapsing multiple sclerosis treated with ozanimod vs interferon β-1A in the phase 3 SUNBEAM trial
    DeLuca, J.
    Brochet, B.
    Kantor, D.
    Cohen, J. A.
    Montalban, X.
    Riolo, J. V.
    Wredendal, E.
    Cheng, C. -Y.
    Silva, D.
    Hartung, H. -P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 881 - 882
  • [8] Relationships between on-treatment changes in glial fibrillary acidic protein levels and clinical outcomes in patients with relapsing multiple sclerosis: post hoc analysis of the phase 3 ozanimod SUNBEAM trial
    Harris, S.
    Comi, G.
    Cree, B. A. C.
    Arnold, D. L.
    Steinman, L.
    Sheffield, J. K.
    Maddux, R.
    Southworth, H.
    Kappos, L.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 507 - 508
  • [9] Evaluating No Evidence of Disease Activity (NEDA) in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod
    Kappos, L.
    Comi, G.
    Selmaj, K. W.
    Steinman, L.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E. K.
    Pachai, C.
    Sheffield, J. K.
    Cheng, C. Y.
    Silva, D.
    Vaile, J.
    Morello, J. P.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 11 - 12
  • [10] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
12345